Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Consapevolezza per i delinquenti che abusano di alcol (MIT)

11 novembre 2026 aggiornato da: Kent Kiehl, The Mind Research Network

Over half of state and federal prisoners meet clinical criteria for alcohol abuse or dependence, and after release from prison, over three-quarters of offenders are re-arrested within five years. Thus, there is a critical need for more effective interventions that could help disrupt this insidious cycle of alcohol abuse, criminal behavior, and incarceration. This project will support the development and evaluation of a mindfulness intervention for female prison inmates that will target key neuropsychological vulnerabilities that are associated with relapse and recidivism.

Panoramica dello studio

Descrizione dettagliata

The pernicious link between substance abuse and criminal behavior imposes major costs to society, totaling billions of dollars in the U.S. annually. There is a critical need for more effective interventions to counteract the high rates of relapse and recidivism in alcohol and substance abusing criminal offenders. Periods of offender incarceration provide a unique opportunity to develop and deploy such interventions. Progress in intervention development could be achieved by targeting specific cognitive and affective vulnerabilities that are common among substance abusing criminal offenders. Preliminary studies suggest that meditative or mindfulness interventions may confer significant psychological and behavioral benefits to inmates. However, the mechanisms and extent of intervention efficacy are unclear, as these previous studies have been beset by a number of methodological limitations. Moreover, to date no study has examined the neurobiological mechanisms that relate to treatment success in this population. NIAAA has recently made a program call to address these issues (PA-15-299). Here we answer this program call and propose to undertake a rigorous and comprehensive longitudinal study of mindfulness treatment of alcohol and substance use disorders among female inmates. This project will randomly assign over 400 female inmates to a mindfulness or relapse prevention training course, and both will be compared against a no treatment control. The mindfulness intervention will be tailored to address two key neuropsychological deficits in alcohol abusing criminal offenders: impulsivity and craving. We will test hypotheses about the neural changes over time with treatment to elucidate mechanisms of change. We will obtain estimates of "real-world" efficacy of the intervention by collecting outcome measures in prison (conduct reports) and following release (alcohol use relapse and antisocial behavior). This project takes advantage of a unique, longstanding partnership between the research team and the states of New Mexico and Wisconsin Correction Departments that allows collection of comprehensive assessment data from inmates during incarceration, including brain imaging data with a mobile MRI scanner, as well as access to post-release outcomes and relapse data. Completion of these aims is a critical step for implementing and evaluating a promising mindfulness intervention for this high-risk population. The proposed research will also begin to elucidate the psychological and neurobiological mechanisms of the treatment. These results will thus significantly advance a program of research seeking to translate the growing knowledge of neuropsychological deficits into more targeted and effective treatments for alcohol and substance abuse problems in criminal offenders.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

176

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • The Mind Research Network

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • 18-65 years of age
  • Alcohol Use Disorder
  • Female (biological sex at birth)
  • Time to release from incarceration > 3 months
  • 5th grade or higher reading level
  • Able to speak and understand English

Exclusion Criteria:

  • Uncorrectable auditory or visual deficits
  • Intelligence Quotient score below 70
  • History of dementia or other cognitive disability
  • Current psychotic disorder (chronic schizophrenia or schizoaffective disorder and/or active psychotic symptoms)
  • Major medical illness or Central Nervous System disease
  • MRI incompatibility (e.g., metal in body)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Trattamento come al solito
Nessun intervento: Controllo della lista d'attesa
Sperimentale: Prevenzione delle ricadute

Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).

Sperimentale: Mindfulness

Mindfulness

Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline Alcohol Craving
Lasso di tempo: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.

Penn Alcohol Craving Scale. 5-item, self-report measure assessing frequency, intensity, and duration of craving, and overall rating of craving for the previous week. Total score range 0-30. Higher scores indicate higher craving.

Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Change From Baseline Daily Depression
Lasso di tempo: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.

Beck Depression Inventory-II (BDI-II). Assesses participants' self-reported depression in the past two weeks. Data for total scores is provided (range: 0-63). Higher scores indicate increased severity of depressive symptoms.

Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Change From Baseline Perception of Quality of Life
Lasso di tempo: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.

World Health Organization Quality of Life - Brief (WHOQOL-BREF). 26-item, self-report measure assessing how individuals perceive their quality of life across domains. Data for psychological health is reported (range: 6-30). Higher scores indicate increased psychological health.

Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Proportion of Participants Who Were Not Arrested Following Release From Incarceration
Lasso di tempo: 30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.

Arrests on misdemeanor and felony charges were the categories used to track criminal behavior in the study participants. To evaluate the effect of the treatment on criminal behavior, we used official state databases to track criminal activity for participants who were released from incarceration post-treatment.

30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.
Participant Reflections on Their Treatment Program
Lasso di tempo: Post-treatment (immediately after 8-week treatment ended)

During the last session of treatment, participants were given a "Reflections on the Course" handout, where they provided feedback on the treatment they received. Participants were asked to provide a rating to the following question:

  • Question 1: On a scale of 1 (not at all) to 10 (very), how important has this program been to you?
Post-treatment (immediately after 8-week treatment ended)
Investigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment
Lasso di tempo: Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.

Salience Alcohol Task (SAT): A drug-cue reactivity functional Magnetic Resonance Imaging (fMRI) task, whereby participants viewed different stimuli (i.e., alcohol cues, negatively valanced stimuli, or neutrally valanced stimuli). After seeing each image, participants were asked to respond to which type of image they saw (i.e., alcohol cues, neutral cues, and negatively valanced cues). Participants completed this task pre-/post-treatment. Independent component analysis was used to extract brain regions related to alcohol cue reactivity, in order to assess functional connectivity changes related to treatment between these regions. Values below represent positive change in z-scores (post - pre-treatment) related to increased functional network connectivity between the anterior cingulate cortex and anterior insula, regions commonly involved in salience detection. A z-score of 0 represents the population mean. All four groups showed increased functional connectivity with z-scores above 0.

Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 luglio 2018

Completamento primario (Effettivo)

30 aprile 2025

Completamento dello studio (Effettivo)

30 aprile 2025

Date di iscrizione allo studio

Primo inviato

18 marzo 2019

Primo inviato che soddisfa i criteri di controllo qualità

19 marzo 2019

Primo Inserito (Effettivo)

21 marzo 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi